vs
Frontier Communications Parent, Inc.（FYBR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Frontier Communications Parent, Inc.的季度营收约是Revvity的2.0倍（$1.5B vs $772.1M），Revvity净利率更高（12.7% vs -5.0%，领先17.7%），Revvity同比增速更快（5.9% vs 4.2%），Revvity自由现金流更多（$161.8M vs $-315.0M），过去两年Revvity的营收复合增速更高（9.0% vs 4.3%）
前沿通信母公司是一家美国电信企业，隶属于威瑞森，拥有光纤通信网络，并提供云相关服务，该公司曾先后更名为公民公用事业公司、公民通信公司和前沿通信公司，是美国本土知名电信运营商之一。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FYBR vs RVTY — 直观对比
营收规模更大
FYBR
是对方的2.0倍
$772.1M
营收增速更快
RVTY
高出1.6%
4.2%
净利率更高
RVTY
高出17.7%
-5.0%
自由现金流更多
RVTY
多$476.8M
$-315.0M
两年增速更快
RVTY
近两年复合增速
4.3%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $772.1M |
| 净利润 | $-76.0M | $98.4M |
| 毛利率 | 64.3% | — |
| 营业利润率 | 7.6% | 14.5% |
| 净利率 | -5.0% | 12.7% |
| 营收同比 | 4.2% | 5.9% |
| 净利润同比 | 7.3% | 3.9% |
| 每股收益（稀释后） | $-0.30 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FYBRRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $1.5B | $698.9M | ||
| Q2 25 | $1.5B | $720.3M | ||
| Q1 25 | $1.5B | $664.8M | ||
| Q4 24 | $1.5B | $729.4M | ||
| Q3 24 | $1.5B | $684.0M | ||
| Q2 24 | $1.5B | $691.7M | ||
| Q1 24 | $1.4B | $649.9M |
净利润FYBRRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $-76.0M | $46.7M | ||
| Q2 25 | $-123.0M | $53.9M | ||
| Q1 25 | $-64.0M | $42.2M | ||
| Q4 24 | $-118.0M | $94.6M | ||
| Q3 24 | $-82.0M | $94.4M | ||
| Q2 24 | $-123.0M | $55.4M | ||
| Q1 24 | $1.0M | $26.0M |
毛利率FYBRRVTY
| Q4 25 | — | — | ||
| Q3 25 | 64.3% | 53.6% | ||
| Q2 25 | 65.0% | 54.5% | ||
| Q1 25 | 65.2% | 56.5% | ||
| Q4 24 | 64.2% | — | ||
| Q3 24 | 63.4% | 56.3% | ||
| Q2 24 | 64.8% | 55.7% | ||
| Q1 24 | 63.9% | 54.6% |
营业利润率FYBRRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | 7.6% | 11.7% | ||
| Q2 25 | 2.9% | 12.6% | ||
| Q1 25 | 5.1% | 10.9% | ||
| Q4 24 | 5.8% | 16.3% | ||
| Q3 24 | 5.8% | 14.3% | ||
| Q2 24 | 6.2% | 12.4% | ||
| Q1 24 | 6.2% | 6.8% |
净利率FYBRRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | -5.0% | 6.7% | ||
| Q2 25 | -8.1% | 7.5% | ||
| Q1 25 | -4.3% | 6.4% | ||
| Q4 24 | -7.9% | 13.0% | ||
| Q3 24 | -5.6% | 13.8% | ||
| Q2 24 | -8.4% | 8.0% | ||
| Q1 24 | 0.1% | 4.0% |
每股收益（稀释后）FYBRRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $-0.30 | $0.40 | ||
| Q2 25 | $-0.49 | $0.46 | ||
| Q1 25 | $-0.26 | $0.35 | ||
| Q4 24 | $-0.48 | $0.77 | ||
| Q3 24 | $-0.33 | $0.77 | ||
| Q2 24 | $-0.49 | $0.45 | ||
| Q1 24 | $0.00 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $336.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.7B | $7.3B |
| 总资产 | $21.6B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FYBRRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $336.0M | $931.4M | ||
| Q2 25 | $412.0M | $991.8M | ||
| Q1 25 | $506.0M | $1.1B | ||
| Q4 24 | $750.0M | $1.2B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $1.2B | $2.0B | ||
| Q1 24 | $1.5B | $1.7B |
股东权益FYBRRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $4.7B | $7.4B | ||
| Q2 25 | $4.8B | $7.6B | ||
| Q1 25 | $4.9B | $7.6B | ||
| Q4 24 | $4.9B | $7.7B | ||
| Q3 24 | $5.1B | $7.9B | ||
| Q2 24 | $5.1B | $7.9B | ||
| Q1 24 | $5.3B | $7.8B |
总资产FYBRRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $21.6B | $12.1B | ||
| Q2 25 | $21.3B | $12.4B | ||
| Q1 25 | $20.9B | $12.4B | ||
| Q4 24 | $20.6B | $12.4B | ||
| Q3 24 | $20.9B | $12.8B | ||
| Q2 24 | $20.2B | $13.4B | ||
| Q1 24 | $20.2B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $504.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-315.0M | $161.8M |
| 自由现金流率自由现金流/营收 | -20.5% | 21.0% |
| 资本支出强度资本支出/营收 | 53.4% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-1.4B | $509.4M |
8季度趋势，按日历期对齐
经营现金流FYBRRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $504.0M | $138.5M | ||
| Q2 25 | $477.0M | $134.3M | ||
| Q1 25 | $519.0M | $128.2M | ||
| Q4 24 | $294.0M | $174.2M | ||
| Q3 24 | $618.0M | $147.9M | ||
| Q2 24 | $374.0M | $158.6M | ||
| Q1 24 | $335.0M | $147.6M |
自由现金流FYBRRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $-315.0M | $120.0M | ||
| Q2 25 | $-368.0M | $115.5M | ||
| Q1 25 | $-238.0M | $112.2M | ||
| Q4 24 | $-498.0M | $149.8M | ||
| Q3 24 | $-81.0M | $125.6M | ||
| Q2 24 | $-252.0M | $136.6M | ||
| Q1 24 | $-331.0M | $129.7M |
自由现金流率FYBRRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | -20.5% | 17.2% | ||
| Q2 25 | -24.2% | 16.0% | ||
| Q1 25 | -15.9% | 16.9% | ||
| Q4 24 | -33.4% | 20.5% | ||
| Q3 24 | -5.5% | 18.4% | ||
| Q2 24 | -17.2% | 19.7% | ||
| Q1 24 | -22.9% | 20.0% |
资本支出强度FYBRRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 53.4% | 2.6% | ||
| Q2 25 | 55.5% | 2.6% | ||
| Q1 25 | 50.6% | 2.4% | ||
| Q4 24 | 53.2% | 3.4% | ||
| Q3 24 | 47.5% | 3.3% | ||
| Q2 24 | 42.7% | 3.2% | ||
| Q1 24 | 46.1% | 2.7% |
现金转化率FYBRRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 335.00× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FYBR
| Consumer | $826.0M | 54% |
| Business And Wholesale | $707.0M | 46% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
